339,276 Shares in Maze Therapeutics, Inc. $MAZE Bought by ADAR1 Capital Management LLC

Key Points

• ADAR1 Capital Management acquired 339,276 Maze Therapeutics shares worth approximately $10.1 million, giving it a 0.61% stake. Several other institutional investors also increased their holdings.
• Insiders sold shares under pre-arranged Rule 10b5-1 plans, including CMO Harold Bernstein’s $445,681 sale and Atul Dandekar’s $205,050 sale; insiders sold $3.06 million in stock over the past three months.
• Analyst sentiment remains broadly positive, with an average “Buy” rating and a $66 consensus price target, although some firms issued “Sell” or downgraded ratings. MAZE opened at $30.42, while the company continues to report losses as a clinical-stage biotech.

ADAR1 Capital Management LLC acquired a new position in Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) during the second quarter, according to the company in its most recent filing with the SEC. The fund acquired 339,276 shares of the company's stock, valued at approximately $10,124,000. ADAR1 Capital Management LLC owned approximately 0.61% of Maze Therapeutics at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Royal Bank of Canada increased its holdings in Maze Therapeutics by 128.3% during the 4th quarter. Royal Bank of Canada now owns 646 shares of the company's stock worth $27,000 after purchasing an additional 363 shares during the last quarter. Ameritas Investment Partners Inc. boosted its stake in Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company's stock valued at $42,000 after acquiring an additional 738 shares during the last quarter. California State Teachers Retirement System boosted its stake in Maze Therapeutics by 138.0% during the 4th quarter. California State Teachers Retirement System now owns 1,321 shares of the company's stock valued at $55,000 after acquiring an additional 766 shares during the last quarter. Police & Firemen s Retirement System of New Jersey grew its holdings in Maze Therapeutics by 18.5% during the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 5,961 shares of the company's stock worth $247,000 after acquiring an additional 931 shares in the last quarter. Finally, Legal & General Group Plc grew its holdings in Maze Therapeutics by 23.0% during the 3rd quarter. Legal & General Group Plc now owns 5,219 shares of the company's stock worth $135,000 after acquiring an additional 977 shares in the last quarter.

Insider Activity at Maze Therapeutics

In related news, CMO Harold Bernstein sold 16,142 shares of the firm's stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $27.61, for a total value of $445,680.62. Following the sale, the chief marketing officer directly owned 16,142 shares in the company, valued at $445,680.62. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of Maze Therapeutics stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $27.34, for a total value of $205,050.00. Following the sale, the insider directly owned 26,250 shares in the company, valued at $717,675. The trade was a 22.22% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 108,110 shares of company stock worth $3,057,531 in the last three months. 5.30% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on MAZE. BTIG Research restated a "buy" rating and issued a $46.00 target price on shares of Maze Therapeutics in a research note on Wednesday, August 12th. Wall Street Zen downgraded Maze Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 15th. Weiss Ratings reissued a "sell (d-)" rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. Finally, TD Cowen raised Maze Therapeutics to a "strong-buy" rating in a report on Monday. Three research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $66.00.

Maze Therapeutics Price Performance

Shares of NASDAQ:MAZE opened at $30.42 on Wednesday. The company has a market cap of $1.69 billion, a PE ratio of -12.07 and a beta of 2.21. Maze Therapeutics, Inc. has a fifty-two week low of $13.28 and a fifty-two week high of $53.65. The firm has a 50-day simple moving average of $28.55 and a 200 day simple moving average of $32.15. The company has a quick ratio of 18.31, a current ratio of 18.31 and a debt-to-equity ratio of 0.09.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.76). On average, sell-side analysts anticipate that Maze Therapeutics, Inc. will post -2.69 EPS for the current year.

About Maze Therapeutics

Maze Therapeutics, Inc NASDAQ: MAZE is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.

Want to see what other hedge funds are holding MAZE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.